BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress
- Cleared dose-limiting toxicity observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma cohort readout in 2H23 - Initiated the potentially... | March 23, 2023